Clinical trials: Hidradenitis Suppurativa
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06959225
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 580 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS.
- Trial name
- Mainsail (NCT07384975)
- Testing
- NAV-240
- Where
- 41 sites in United States, Bulgaria and 6 more
- Volunteers
- 150 people
- Sponsor
- Navigator Medicines, Inc.
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and…
- Trial name
- ANIMA (NCT05921994)
- Testing
- secukinumab
- Where
- 80 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection
Myriad™ Augmented Soft Tissue Reconstruction Registry
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures.
- Conditions
- Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus
- Trial name
- MASTRR (NCT05243966)
- Testing
- Myriad Matrix™ and Myriad Morcells™
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- Aroa Biosurgery Limited
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
- Trial name
- CEDAR (NCT06685835)
- Testing
- Brensocatib
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 214 people
- Sponsor
- Insmed Incorporated
Hidradenitis Suppurativa
Real-world Secukinumab Outcomes in Canadian HS Patients
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab…
- Trial name
- HS-RISE (NCT07282015)
- Where
- 15 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in…
- Trial name
- NCT06785675
- Testing
- Secukinumab
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411379
- Testing
- Sonelokimab
- Where
- 106 sites in United States, Belgium and 10 more
- Volunteers
- 418 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
- Trial name
- NCT07007637
- Testing
- Sonelokimab
- Where
- 166 sites in United States, Belgium and 14 more
- Volunteers
- 835 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
A Study of LAD191 in Adults With Hidradenitis Suppurativa
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability…
- Trial name
- NCT07151937
- Testing
- LAD191, Adalimumab
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Almirall, S.A.
Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
- Trial name
- NCT06768671
- Testing
- Sonelokimab
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa (HS)
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT07244510
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LOTUS (NCT06603077)
- Testing
- AVTX-009 Regimen 1, AVTX-009 Regimen 2
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 253 people
- Sponsor
- Avalo Therapeutics, Inc.
Hidradenitis Suppurativa
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).
- Trial name
- ANIMA-R (NCT06517732)
- Testing
- Secukinumab
- Where
- 19 sites in Russia
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
- Trial name
- NCT07123038
- Testing
- Long Term Safety Monitoring Procedures
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation